{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol+%28E2%29&page=2",
    "query": {
      "intervention": "Estradiol (E2)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 47,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol+%28E2%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol+%28E2%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T03:30:10.672Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02272647",
      "title": "Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "IM Saline Placebo (0.25 ml)",
          "type": "DRUG"
        },
        {
          "name": "IM Estradiol valerate (2.5 mg)",
          "type": "DRUG"
        },
        {
          "name": "IM Saline Placebo (0.5 ml)",
          "type": "DRUG"
        },
        {
          "name": "IM Estradiol valerate (5.0 mg)",
          "type": "DRUG"
        },
        {
          "name": "Oral Micronized Progesterone",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ghrelin (0.3 ug/kg)",
          "type": "DRUG"
        },
        {
          "name": "Medroxyprogesterone - Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 80 Years · Female only"
      },
      "enrollment_count": 47,
      "start_date": "2014-12",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2018-03-22",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02272647"
    },
    {
      "nct_id": "NCT00328926",
      "title": "Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypogonadotropic Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Luveris® 75 IU",
          "type": "DRUG"
        },
        {
          "name": "Luveris® 25 IU",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human follicle stimulating hormone (r-hFSH)",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human chorionic gonadotropin (r-hCG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2006-03",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-08-07",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00328926"
    },
    {
      "nct_id": "NCT03412890",
      "title": "LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heavy Menstrual Bleeding",
        "Uterine Fibroid"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 477,
      "start_date": "2017-10-19",
      "completion_date": "2021-01-13",
      "has_results": true,
      "last_update_posted_date": "2024-05-09",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 104,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03412890"
    },
    {
      "nct_id": "NCT02026973",
      "title": "Impact of Endogenous E2 on SSI and GH Rebound",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Somatostatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "55 Years to 80 Years · Female only"
      },
      "enrollment_count": 62,
      "start_date": "2014-03",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-03-16",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02026973"
    },
    {
      "nct_id": "NCT03103087",
      "title": "LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heavy Menstrual Bleeding",
        "Uterine Fibroid"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate",
          "type": "DRUG"
        },
        {
          "name": "Relugolix placebo",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 382,
      "start_date": "2017-06-14",
      "completion_date": "2020-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-04-20",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 89,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03103087"
    },
    {
      "nct_id": "NCT01200537",
      "title": "Optimizing Ovulation Induction in the Poor Responder",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "IVF Poor Responders"
      ],
      "interventions": [
        {
          "name": "Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Oral Contraceptive Pills (OCP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 50 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2010-10",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2012-11-21",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01200537"
    },
    {
      "nct_id": "NCT01586000",
      "title": "A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Suppression of Ovulation"
      ],
      "interventions": [
        {
          "name": "10 µg/day E2 with NES 200® µg/day",
          "type": "DRUG"
        },
        {
          "name": "20 µg/day E2 with NES 200® µg/day",
          "type": "DRUG"
        },
        {
          "name": "40 µg/day E2 with NES 200® µg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kimberly Myer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 39 Years · Female only"
      },
      "enrollment_count": 197,
      "start_date": "2012-03",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 8,
      "location_summary": "Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 4 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01586000"
    },
    {
      "nct_id": "NCT05862272",
      "title": "A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uterine Fibroids",
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Relugolix Combination Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma Switzerland GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 1000,
      "start_date": "2023-08-14",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 120,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05862272"
    },
    {
      "nct_id": "NCT04225221",
      "title": "Neurobiology of Bulimia Nervosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bulimia Nervosa"
      ],
      "interventions": [
        {
          "name": "Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Micronized progesterone",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 42 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2020-02-24",
      "completion_date": "2022-04-04",
      "has_results": true,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225221"
    },
    {
      "nct_id": "NCT00870220",
      "title": "Initiating Transdermal Estradiol Therapy in Turner's Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Turner's Syndrome"
      ],
      "interventions": [
        {
          "name": "Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "138 Months",
        "maximum_age": "13 Years",
        "sex": "FEMALE",
        "summary": "138 Months to 13 Years · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2009-04",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2014-03-11",
      "last_synced_at": "2026-10-08T03:30:10.672Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00870220"
    }
  ]
}